Preparation and biological evaluation of [99mTc/EDDA/Tricine/ HYNIC0, BzThi3]-octreotide for somatostatin receptor-positive tumor imaging

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 3, 2013, Pages 240-247

  Erfani, Mostafa ^a   Shafiei, Mohammad ^a   Mazidi, Mohammad ^a   Goudarzi, Mostafa ^a  

^a NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

Author keywords

99mTc; HYNIC; Internalization; Octreotide; Somatostatin receptor; Tumor

Indexed keywords

[6 HYDRAZINOPYRIDINE 3 CARBOXYLIC ACID, BETA(3 BENZOTHIENYL)ALANINE]OCTREOTIDE TC 99M; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; RAT; RECEPTOR BINDING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STRUCTURE ACTIVITY RELATION; THIN LAYER CHROMATOGRAPHY;

ANIMALS; HUMANS; MALE; OCTREOTIDE; ORGANOTECHNETIUM COMPOUNDS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN; TISSUE DISTRIBUTION;

EID: 84876106157     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1270     Document Type: Article

References (39)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389
2. Weiner RE, Thakur ML. Radiolabeled peptides in oncology: Role in diagnosis and treatment. Bio Drugs 2005;19:145
3. Reubi JC, Maecke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46:67S.
4. Heppeler A, Froidevaux S, Eberle AN, et al. Receptor targeting for tumor localization and therapy with radiopeptides. Curr Med Chem 2000;7:971
5. Boerman OC, Oyen WJ, Corstens FH. Radiolabeled receptorbinding peptides: A new class of radiopharmaceuticals. Semin Nucl Med 2000;30:195
6. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I- Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716
7. Meyer GJ, Maecke H, Schuhmacher J, et al. 68Ga-Labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004;31:1097
8. Henze M, Schuhmacher J, Hipp P, et al. PET imaging of somatostatin receptors using [68Ga]-DOTA-D-Phe1-Tyr3-octreotide: First results in patients with meningiomas. J Nucl Med 2001;42:1053
9. Anderson CJ, Jones AL, Bass LA, et al. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumorbearing rats. J Nucl Med 1998;39:1944
10. Sprague JE, Peng Y, Sun X, et al. Preparation and biological evaluation of copper-64-labeled Tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 2004;10:8674
11. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumors with the novel radiolabelled somatostatin analogue [177Lu- DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417
12. Teunissen JJ, Kwekkeboom DJ, Kooij PP, et al. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. J Nucl Med 2005;46:107S
13. Stolz B, Weckbecker G, Smith-Jones PM, et al. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90YSMT487) eradicates experimental rat pancreatic CA 20948 tumors. Eur J Nucl Med 1998;25:668
14. Faintuch BL, Pereira NPS, Faintuch S, et al. Direct labeling studies of octapeptides with rhenium-188. Radiochimica Acta 2003;91:427
15. Gandomkar M, Najafi R, Sadat Ebrahimi SE, et al. Direct labelling of octreotide with 99mTc: Effect of different concentration of reducing agents and amount of sodium pertechnetate on radiolabelling efficiency. Appl Radiat Isot 2003;58:361
16. Maina T, Stolz B, Albert R, et al. Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219-387) labelled with technetium-99m. Eur J Nucl Med 1994;21:437
17. Maina T, Nock B, Nikolopoulou A, et al. [99mTc] Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumors: Synthesis and preclinical results. Eur J Nucl Med Mol Imaging 2002;29:742
18. Liu S, Edwards DS, Looby RJ, et al. Labeling cyclic glycoprotein IIb/IIIa receptor antagonists with 99mTc by the preformed chelate approach: Effects of chelators on properties of [99mTc]chelator-peptide conjugates. Bioconjug Chem 1996;7:196
19. Decristoforo C, Melendez-Alafort L, Sosabowski JK, et al. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatinreceptor- positive tumors: Preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 2000;41:1114
20. Spradau TW, Edwards WB, Anderson CJ, et al. Synthesis and Biological Evaluation of Tc-99m-Cyclopentadienyltricarbonyltechnetium- Labeled octreotide. Nucl Med Biol 1999;26:1
21. Abrams MJ, Juweid M, tenKate CI, et al. Technetium-99mhuman polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990;31:2022
22. Gandomkar M, Najafi R, Ebrahimi F, et al. Clinical evaluation of antimicrobial peptide [99mTc/Tricine/HYNIC0] ubiquicidin 29-41 as a human-specific infection imaging agent. Nucl Med Biol 2009;36:199
23. Babich JW, Fischman AJ. Effect of ''co-ligand'' on the biodistribution of 99mTc labeled hydrazino nicotinic acid derivatized chemotactic peptides. Nucl Med Biol 1995;22:25
24. Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836
25. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273
26. Ferone D, van Hagen MP, Kwekkeboom DJ, et al. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 2000;85:1719
27. Papotti M, Croce S, Bello M, et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumors. Correlation with preoperative octreotide scintigraphy. Virchows Arch 2001;439:787
28. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors: Molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging 2003;30:781
29. Forssell-Aronsson EB, Nilsson O, Benjegard SA, et al. 111In- DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 2000;41:636
30. Halmos G, Sun B, Schally AV, et al. Human ovarian cancers express somatostatin receptors. J Clin Endocrinol Metab 2000;85:3509
31. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a highaffinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338
32. Ginj M, Chen J, Walter MA, et al. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 2005;11:1136
33. Gabriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA/HYNICTOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor- expressing tumors. J Nucl Med 2003;44:708
34. Gandomkar M, Najafia R, Shafiei M, et al. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]- octreotide as a new analogue in the detection of somatostatinreceptor- positive tumors. Nucl Med Biol 2007;34:651
35. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32:84
36. Virgolini I, Britton K, Buscombe J, et al. 111In-and 90YDOTA- lanreotide: Results and implications of the Mauritius trial. Semin Nucl Med 2002;32:148
37. De Jong M, Breeman WAP, Bakker WH, et al. Comparision of 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437
38. Storch D, Behe M, Walter MA, et al. Evaluation of [99mTc/ EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: Does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005;46:1561
39. Raulf F, Perez J, Joyer D, et al. Differential expression of five somatostatin receptor subtypes, sstr1-5, in the CNS and peripheral tissue. Digestion 1994;55:46